During his time as CEO of West Pharmaceutical Services, Donald E. Morel, Jr. saw his stock holdings escalate dramatically, reflecting both his confidence in the company and his significant insider trading activities. In 2019, his stock holdings were valued at...

During his time as CEO of West Pharmaceutical Services, Donald E. Morel, Jr. saw his stock holdings escalate dramatically, reflecting both his confidence in the company and his significant insider trading activities. In 2019, his stock holdings were valued at approximately $6.41 million, but this figure saw consistent growth, reaching as high as $26.33 million by September 2021. This trajectory underscores a period of robust performance at West Pharmaceutical as the market recognized the company's advancements in drug delivery systems. Notably, by the time of his retirement in 2015, Morel was firmly positioned with a vested interest in the success of West Pharmaceutical, further influencing his leadership decisions. His wealth in stock holdings fluctuated but showed a generally upward trend, showcasing his ability to capitalize on the company's growth.